Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV000660503 | SCV000782603 | uncertain significance | not provided | 2017-03-02 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV001264830 | SCV001443029 | uncertain significance | Spinocerebellar ataxia, autosomal recessive 28 | 2020-03-01 | criteria provided, single submitter | clinical testing | Review of the variants reported in Reuter et al., 2017, PMID: 28097321: PM2,PM3_Supporting |
Gene |
RCV000660503 | SCV002027684 | uncertain significance | not provided | 2021-11-16 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 28097321) |
Ambry Genetics | RCV002530575 | SCV003729341 | uncertain significance | Inborn genetic diseases | 2021-05-20 | criteria provided, single submitter | clinical testing | The c.137C>A (p.T46N) alteration is located in coding exon 1 of the THG1L gene. This alteration results from a C to A substitution at nucleotide position 137, causing the threonine (T) at amino acid position 46 to be replaced by an asparagine (N). Based on data from the Genome Aggregation Database (gnomAD), the THG1L c.137C>A alteration was observed in 0.006% (2/31406) of total alleles studied, with a frequency of 0.013% (2/15432) in the European (non-Finnish) subpopulation. This alteration has been observed homozygous in two first cousins from one family who presented with mild intellectual disability and ataxia (Reuter, 2017). This amino acid position is highly conserved in available vertebrate species. The p.T46N alteration is predicted to be tolerated by in silico analysis. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |